Abstract: Provided is a substrate processing apparatus including: a chuck configured to support a substrate; a dielectric plate disposed to face an upper surface of the substrate supported by the chuck; a gas supply unit configured to supply process gas to an edge region of the substrate; and a first edge electrode configured to generate plasma from the process gas to the edge region of the substrate supported by the chuck, in which the first edge electrode includes: a plurality of electrode units; and one or more insulating units provided between the electrode units.

Abstract: The present invention relates to a Lactobacillus plantarum GB104 strain (accession number: KCTC 14107BP) and a composition comprising same as active ingredient for prevention or treatment of cancer. The Lactobacillus plantarum GB104 strain according to the present invention increases production of INF-? and granzyme B and activates immune cells such as cytotoxic T cells and NK cells, thereby being able to ultimately inhibit the formation and growth of tumors. Therefore, a composition comprising the Lactobacillus plantarum GB104 strain of the present invention as an active ingredient increases immune activity in the body and thus can be effectively utilized for treatment of cancer diseases and is highly industrially applicable.

Abstract: Provided is an apparatus for processing a substrate, the apparatus including: a chamber having a processing space; a support unit for supporting a substrate in the processing space; a gas supply unit for supplying process gas to the processing space; and a plasma generation unit for generating plasma from the process gas, in which the plasma generation unit includes: an inner coil part including a plurality of inner coils; an outer coil part provided to surround the inner coil part when viewed from above and including a plurality of outer coils; an upper power source for applying power to the inner coil part and the outer coil part, and a ground plate disposed above the inner coil part and the outer coil part and grounding the inner coil part and the outer coil part.

Abstract: An image sensor includes a pixel array in which a plurality of pixels are arranged in a matrix form, each pixel outputting a first pixel datum and a second pixel datum according to a dual conversion gain. The image sensor includes a signal convertor configured to generate first kernel data including first pixel data and second kernel data including second pixel data, which are output from a pixel group including a target pixel and multiple pixels surrounding the target pixel; determine a partial region brightness based on the second pixel data included in the second kernel data; and perform fusion of the first kernel data and the second kernel data based on the partial region brightness.

Abstract: Proposed is a method for quantifying water and lipid contents in turbid media. Methods for quantifying water and lipid contents through non-invasive methods in turbid media in which scattering occurs upon penetration of near-infrared rays have yet to be proposed. In addition, existing apparatuses and methods for measuring body composition use frequency-domain and time-domain diffuse optical spectroscopy or infrared spectroscopy to measure water and lipid contents in tissue, whereby there are limitations that hardware configurations become complicated, and mass production and sales are subject to constraints. To solve such problems, proposed is a method for quantifying water and lipid contents in turbid media using narrowband diffuse reflectance spectroscopy, which uses only a near-infrared band in a range of 900 to 1,000 nm, configured such that the water and lipid contents can be accurately quantified in tissue through a simpler configuration than that in existing methods.

Abstract: The present invention relates to novel 2-Methoxyestradiol derivatives and their medical use. In particular, the novel derivatives of the present invention are useful for the treatment or prevention of liver or lung fibrosis. Accordingly, the present invention also provides medical uses of the 2-Methoxyestradiol derivatives of the present invention. The present invention also provides a method of treating or preventing liver or lung fibrosis comprising administering an effective amount of the 2-Methoxyestradiol derivatives of the present invention.

Abstract: A substrate treating apparatus includes a process treating unit providing a treating space for treating a substrate and a plasma generation unit provided above the process treating unit and generating a plasma from a process gas. The plasma generation unit includes a plasma chamber having a discharge space formed therein, an antenna surrounding an outside of the plasma chamber and flowing a high frequency current therethrough, and a cover member surrounding an outside of the antenna, and wherein the cover member is grounded.

Abstract: An organic light emitting display apparatus is disclosed that comprises a substrate including a first portion and a second portion; a first thin film transistor having a first polycrystalline semiconductor pattern, the first thin film transistor on the first portion of the substrate; a second thin film transistor having a first oxide semiconductor pattern, the second thin film transistor on the second portion of the substrate; and an organic light emitting device configured to emit light, the organic light emitting device connected to the second thin film transistor; wherein the first polycrystalline semiconductor pattern includes a surface that is planarized and the first oxide semiconductor pattern includes a surface that includes a plurality of protrusions.

Abstract: The present invention provides a pharmaceutical composition for protecting or mitigating radiation against radiation-induced damage, comprising a compound of Formula 1, or a pharmaceutically acceptable salt or solvate thereof. Further, the present invention provides a pharmaceutical composition for preventing or treating pulmonary fibrosis, comprising a compound of Formula 1, or a pharmaceutically acceptable salt or solvate thereof.

Abstract: Provided is a substrate processing apparatus including: a chuck configured to support a substrate; a dielectric plate disposed to face an upper surface of the substrate supported by the chuck; a gas supply unit configured to supply process gas to an edge region of the substrate; and a first edge electrode configured to generate plasma from the process gas to the edge region of the substrate supported by the chuck, in which the first edge electrode includes: a plurality of electrode units; and one or more insulating units provided between the electrode units.

Abstract: The present disclosure relates to a novel method for synthesizing DHPV, and more particularly, to a novel method for synthesizing DHPV (5-(3?,4?-dihydroxyphenyl)-?-valerolactone)) which is a major metabolite of cacao. This method has the advantage of not only facilitating a large-scale synthesis by a new synthesis method that can overcome existing defects, but also making it easy to select antioxidants and isomers exhibiting anti-aging bioactivities. Therefore, it is effective in enabling mass production of DHPV having high value as a functional material for cosmetics and pharmaceuticals in a simple and economical manner.

Abstract: The present invention provides a pharmaceutical composition for inhibiting DNA damage, comprising a GSK3 inhibitor. Further, the present invention provides a pharmaceutical composition for protecting or mitigating radiation against radiation-induced damage, or preventing or treating pulmonary fibrosis, comprising a GSK3 inhibitor.

Abstract: The present disclosure relates to a novel method for synthesizing DHPV, and more particularly, to a novel method for synthesizing DHPV (5-(3?,4?-dihydroxyphenyl)-?-valerolactone)) which is a major metabolite of cacao. This method has the advantage of not only facilitating a large-scale synthesis by a new synthesis method that can overcome existing defects, but also making it easy to select antioxidants and isomers exhibiting anti-aging bioactivities. Therefore, it is effective in enabling mass production of DHPV having high value as a functional material for cosmetics and pharmaceuticals in a simple and economical manner.

Abstract: A first electronic device is provided. The first electronic device includes a communication module and a controller that is configured to request a data list from a second electronic device based on a detection of a charging state of a battery of the first electronic device, receive the data list corresponding to the request, and request at least some elements of data in the received data list from the second electronic device.

Abstract: The present invention relates to a pharmaceutical composition for radioprotection or radiomitigation with respect to radiation-induced damage, the composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof or a solvate thereof.

Abstract: A first electronic device is provided. The first electronic device includes a communication module and a controller that is configured to request a data list from a second electronic device based on a detection of a charging state of a battery of the first electronic device, receive the data list corresponding to the request, and request at least some elements of data in the received data list from the second electronic device.

Abstract: A first electronic device is provided. The first electronic device includes a communication module and a controller that is configured to request a data list from a second electronic device based on a detection of a charging state of a battery of the first electronic device, receive the data list corresponding to the request, and request at least some elements of data in the received data list from the second electronic device.

Abstract: The present invention relates to a photoaging inhibitor, and more specifically it relates to a pharmaceutical composition, a food composition or a cosmetic composition for preventing, improving or treating photoaging of skin, comprising DHPV (5-(3?,4?-Dihydroxyphenyl)-?-valerolactone) which is a metabolite of cacao. Since DHPV, an active ingredient comprised in the composition according to the present invention is a metabolite of cacao which is a botanical raw material harmless to human body and is not only excellent in biosafety, but also regulates expression of proteins related to skin aging epigenetically, thereby exhibiting an excellent skin aging-preventing function at a low concentration of 1 nM based on skin cells, the composition comprising the same is excellent in use as medicines, cosmetics and foods for preventing, improving and treating skin aging.

Abstract: The present invention relates to a pharmaceutical composition for radioprotection or radiomitigation with respect to radiation-induced damage, the composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof or a solvate thereof.

Abstract: The present invention relates to a preparation method of drug-containing sustained release microparticles, the preparation method comprising the steps of: (a) dissolving a biodegradable polymer and a drug in a halogenated alkane solvent to form a drug-containing biodegradable polymer solution; (b) homogeneously mixing the drug-containing biodegradable polymer solution in a continuous phase containing a surfactant to form a dispersed phase; (c) maintaining an emulsion comprising the continuous phase and the dispersed phase at a temperature lower than the boiling point of the halogenated alkane solvent to form microparticles in the continuous phase; (d) primarily drying the microparticles; (e) mixing the primarily dried microparticles with an aqueous alcohol solution, and then maintaining the aqueous alcohol solution at a temperature no less than the boiling point of the halogenated alkane solvent to extract and evaporate the remaining halogenated alkane solvent from the microparticles; and (f) secondarily dryi